Supplement Label Index

R-Lipoic acid (R-ALA, natural enantiomer, free acid) vs. Sodium R-lipoate (Na-R-ALA, stabilized R-lipoic acid)

Among 307 on-market alpha-lipoic acid products with an identifiable primary form, 61.6% use R-Lipoic acid (R-ALA, natural enantiomer, free acid) (189 products) and 17.9% use Sodium R-lipoate (Na-R-ALA, stabilized R-lipoic acid) (55).

R-Lipoic acid (R-ALA, natural enantiomer, free acid)Sodium R-lipoate (Na-R-ALA, stabilized R-lipoic acid)
Quality tierUnratedUnrated
Alpha-Lipoic Acid by weight——
Share of market61.6%17.9%
On-market products18955
Median declared dose100 mg
middle half: 50–150
150 mg
middle half: 50–200
Most common brandsBulkSupplements.com, Life Extension, NFHBlue Star Nutraceuticals, Universal, SuperSmart

Doses are declared per serving in mg. “By weight” is the share of the ingredient that is the nutrient itself (e.g. elemental magnesium in a magnesium salt).

Why R-Lipoic acid (R-ALA, natural enantiomer, free acid) is unrated

The naturally occurring enantiomer; the free acid is described as unstable/poorly soluble. In one randomized crossover (n=20, progressive MS), 600 mg R-LA was bioequivalent in R-LA AUC/Cmax to 1,200 mg racemic R,S-LA and caused fewer GI side effects (Cameron 2020); a pilot (Keith 2012) found variable, age-dependent differences. No outcome trial compares them, so it is not ranked.

Source: Cameron M et al. 2020, J Clin Pharmacol 60(8):1099-1106, PMID 32212340; Keith DJ et al. 2012, Pharmacol Res 66(3):199-206, PMID 22609537; Carlson DA et al. 2007, Altern Med Rev 12(4):343-351, PMID 18069903 (background statement; study itself tested the sodium salt)

Why Sodium R-lipoate (Na-R-ALA, stabilized R-lipoic acid) is unrated

One small (n=12) PK study, from the lab that had run the earlier preliminary study, reported significantly higher Cmax and AUC and shorter Tmax for the sodium salt than for R-lipoic acid or racemic ALA, but the comparison extends an earlier preliminary study, and no outcome trials exist -- insufficient to rank. Salt weight is ~10% above acid weight; labels usually declare acid equivalents, so amounts are used as declared.

Source: Carlson DA et al. 2007, Altern Med Rev 12(4):343-351, PMID 18069903

Tiers summarize published comparative bioavailability or outcome evidence for each form (see methodology). This page describes the market; it is not a recommendation to take either form. Talk to a clinician about what's right for you.

Other alpha-lipoic acid comparisons